Læknablaðið - 01.07.2016, Síða 15

LÆKNAblaðið 2016/102 331
R A N N S Ó K N
ENGLISH SUMMARY
Introduction: Hemolytic disease of the fetus and newborn (HDFN)
is caused by the destruction of fetal red blood cells due to red cell
antibodies produced by the mother. HDFN can cause fetal hydrops
during pregnancy or neonatal jaundice after birth. Direct Antiglobulin
Test (DAT) detects antibodies bound to red cells and is a valuable test
aiding in the diagnosis of HDFN. In Iceland DAT is routinely performed on
cord blood or newborn blood samples if the mother is Rhesus D negati-
ve or has non-A/B red cell alloantibodies. The aim of this study was to
investigate the causes and consequences of positive DAT in newborns in
Iceland over a period of eight years.
Material and methods: The study population was infants diagnosed
with a positive DAT in the Blood Bank in Iceland in the years 2005-2012.
Relevant data on the blood group and antibody status of mother and
child, blood transfusion and DAT results were retrieved from the Blood
Bank information system ProSang. Birth records provided information on
birth weight, gestational age and phototherapy. Health records from the
Children's Hospital provided information on the management and fate of
the newborn.
Results: Over the study period 383 newborns had a positive DAT result
at the Blood Bank. In 73.6% of cases the underlying cause was ABO
blood group mismatch between mother and infant, in 20.4% of cases
the mother had non-A/B red cell alloantibodies, in 3.9% both of above
factors were present, while in 2.1% the cause was unclear. A total of 179
(47.6%) children had neonatal jaundice that required treatment, of which
167 (93.3%) only needed phototherapy. Eight infants required exchange
transfusion, five of these had Rhesus antibodies and three ABO blood
group mismatch.
Conclusion: ABO blood group mismatch between mother and child
was the most common cause for a positive DAT in neonates in Iceland
in the years 2005-2012. Almost half of the neonates required treatment
but usually phototherapy was sufficient. Rarely, blood transfusion or
exchange transfusion was necessary in severe cases of ABO blood
group mismatch or non-A/B red cell alloantibodies.
Positive Coomb’s test in newborns; causes and clinical consequences
Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012
Thordis Kristinsdottir1, Sveinn Kjartansson2, Hildur Hardardottir1,3, Thorbjörn Jonsson4, Anna Margret Halldorsdottir4
1Faculty of Medicine, University of Iceland, 2Children's Hospital of Landspítali, 3Department of Obstetrics and Gynecology, Landspítali, 4The Blood Bank, Landspítali.
Key words: Coombs test, Direct Antiglobulin Test (DAT), Hemolytic disease of the fetus and newborn (HDFN), ABO blood group mismatch, red cell alloantibodies, neonatal jaundice,
exchange transfusion.
Correspondence: Anna Margrét Halldórsdóttir, annamha@landspitali.is
Heimildir
1. Poole J, Daniels G. Blood group antibodies and their sign-
ificance in transfusion medicine. Transfus Med Rev 2007;
21: 58-71.
2. Harmening DM. Modern Blood Banking & Transfusion
Practices. 5th ed. F.A. Davis Company, Fíladelfíu,
Bandaríkjunum 2005.
3. Chen JY, Ling UP. Prediction of the development of
neonatal hyperbilirubinemia in ABO incompatibility.
Zhonghua Yi Xue Za Zhi (Taipei) 1994; 53: 13-8.
4. Petrides M, Stack G, Cooling L, Maes LY. Practical Guide
to Transfusion Medicine. 2nd ed. AABB Pres, Bethesda,
Maryland 2007.
5. Murray NA, Roberts IA. Haemolytic disease of the new-
born. Arch Dis Child Fetal Neonatal Ed 2007; 92: F83-F88.
6. Bowman J. Thirty-five years of Rh prophylaxis.
Transfusion 2003; 43: 1661-6.
7. Roberts IA. The changing face of haemolytic disease of the
newborn. Early Hum Dev 2008; 84: 515-23.
8. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R.
Female alloimmunization with antibodies known to cause
hemolytic disease. Obstet Gynecol 1997; 89: 272-5.
9. Hellman-Erlingsson S. Greining blóðflokkamótefna hjá
vanfærum konum og mæðrum á Íslandi 1970-1984.
Læknablaðið 1986; 72: 321-9.
10. Nordvall M, Dziegel M, Hegaard HK, Bidstrup M, Jonsbo
F, Christensen B, et al. Red blood cell antibodies in pregn-
ancy and their clinical consequences: synergistic effects of
multiple specificities. Transfusion 2009; 9: 2070-5.
11. Dinesh D. Review of positive direct antiglobulin tests
found on cord blood sampling. J Paediatr Child Health
2005; 41: 504-7.
12. Coombs RRA, Mourant AE, Race RR. In-vivo isos-
ensitisation of red cells in babies with hæmolytic disease.
Lancet 1946; 247: 264-6.
13. Pediatrics A.A.o. Clinical practice guideline: management
of hyperbilirubinemia in the newborn infant 35 or more
weeks of gestation. Pediatrics 2004; 114: 297-316.
14. Herschel M, Karrison T, Wen M, Caldarelli L, Baron B.
Evaluation of the direct antiglobulin (Coombs') test for
identifying newborns at risk for hemolysis as determined
by end-tidal carbon monoxide concentration (ETCOc);
and comparison of the Coombs' test with ETCOc for det-
ecting significant jaundice. J Perinatol 2002; 22: 341-7.
15. Cortey A, Brossard Y. [Adverse effects and patient
information]. J Gynecol Obstet Biol Reprod (Paris) 2006;
35(1 Suppl): 1S112-1S118.
16. Madan A, Huntsinger K, Burgos A, Benitz WE.
Readmission for newborn jaundice: the value of the
Coombs’ test in predicting the need for phototherapy. Clin
Pediatr 2004; 43: 63-8.
17. Dillon A, Chaudhari T, Crispin P, Shadbolt B, Kent A. Has
anti-D prophylaxis increased the rate of positive direct
antiglobulin test results and can the direct antiglobulin
test predict need for phototherapy in Rh/ABO incompati-
bility? J Paediatr Child Health 2011; 47: 40-3.
18. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell all-
oimmunization. Sem Fetal Neonatal Med 2008; 13: 207-14.
19. McKenna DS, Nagaraja HN, O’Shaughnessy R.
Management of pregnancies complicated by anti-Kell
isoimmunization. Obstet Gynecol 1999; 93: 667-73.
20. Kaplan M, Hammerman C, Vreman HJ, Wong RJ,
Stevenson DK. Hemolysis and hyperbilirubinemia in
antiglobulin positive, direct ABO blood group hetero-
specific neonates. J Pediatr 2010; 157: 772-7.
21. Daniels G, Poole J, De Silva M, Callaghan T, MacLennan
S, Smith N. The clinical significance of blood group
antibodies. Transfus Med 2002; 12: 287-95.
22. American Academy of Pediatrics Subcommittee on
Hyperbilirubinemia. Management of hyperbilirubinemia
in the newborn infant 35 or more weeks of gestation.
Pediatrics 2004; 114: 297-316.
23. Kaplan M, Na'amad M, Kenan A, Rudensky B,
Hammerman C, Vreman HJ, et al. Failure to predict
hemolysis and hyperbilirubinemia by IgG Subclass in
blood group A or B infants born to group O mothers.
Pediatr 2009; 123: e132-e137.
24. Sgro M, Campbell D, Shah V. Incidence and causes of
severe neonatal hyperbilirubinemia in Canada. CMAJ
2006; 175: 587-90.
25. Wainer S, Rabi J, Lyon M. Coombs' testing and neonatal
hyperbilirubinemia. CMAJ 2007; 176: 972-3; author reply
973.
26. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous
immunoglobin (two-dose regimen) in the management
of severe Rh hemolytic disease of newborn--a prospective
randomized controlled trial. Eur J Pediatr 2011; 170: 461-7.
27. Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT,
te Pas AB, Kramer CM, et al. Intravenous immunoglobulin
in neonates with rhesus hemolytic disease: a randomized
controlled trial. Pediatr 2011; 127: 680-6.